CEA, iBiTec-S, Service d'Ingénierie Moléculaire des Protéines, LTMB, Gif-sur-Yvette F-91191, France; Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy.
N Biotechnol. 2015 Jan 25;32(1):54-64. doi: 10.1016/j.nbt.2014.09.002. Epub 2014 Sep 16.
Crystallographic structure determination of protein-ligand complexes of transthyretin (TTR) has been hindered by the low affinity of many compounds that bind to the central cavity of the tetramer. Because crystallization trials are carried out at protein and ligand concentration that approach the millimolar range, low affinity is less of a problem than the poor solubility of many compounds that have been shown to inhibit amyloid fibril formation. To achieve complete occupancy in co-crystallization experiments, the minimal requirement is one ligand for each of the two sites within the TTR tetramer. Here we present a new strategy for the co-crystallization of TTR using high molecular weight polyethylene glycol instead of high ionic strength precipitants, with ligands solubilized in multicomponent mixtures of compounds. This strategy is applied to the crystallization of TTR complexes with curcumin and 16α-bromo-estradiol. Here we report the crystal structures with these compounds and with the ferulic acid that results from curcumin degradation.
蛋白质-配体复合物的晶体结构测定一直受到许多与四聚体中心腔结合的化合物亲和力低的阻碍。因为结晶试验是在接近毫摩尔浓度的蛋白质和配体浓度下进行的,所以低亲和力的问题不如许多已被证明能抑制淀粉样纤维形成的化合物的溶解度差那么严重。为了在共结晶实验中实现完全占据,最小要求是每个 TTR 四聚体的两个位点各有一个配体。在这里,我们提出了一种使用高分子量聚乙二醇而不是高离子强度沉淀剂来共结晶 TTR 的新策略,将配体溶解在多组分化合物混合物中。该策略应用于与姜黄素和 16α-溴雌二醇的 TTR 复合物的结晶。在这里,我们报告了这些化合物以及姜黄素降解产物阿魏酸的晶体结构。